Stockchase Opinions

Robert Floyd Hemosol HML-T DON'T BUY Dec 08, 2003

Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan.
$1.700

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

DON'T BUY
Very speculative. FDA trials didn't go well.
DON'T BUY
Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support.
DON'T BUY
A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward.
DON'T BUY
Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock.
SELL
Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product.
BUY
It will expire again, company has run out of money many times. Take money out, while money is on the table.
TRADE
Speculative future.
DON'T BUY
Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future.
DON'T BUY
This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it.